



Josh has IBD.

You've prescribed a biologic,
but they have questions...

Is it the right dose at the
right interval, for him?



Combines serologic, genetic and inflammatory markers to help differentiate IBD from non-IBD and Crohn's disease from ulcerative colitis.



Noninvasive serum test that assesses endoscopic disease activity as well as therapeutic response in Crohn's disease patients ≥ 12 years old.



Proprietary drug-tolerant HDSA technology that simultaneously measures biologic drug and antibody levels for IFX, ADA, UST, VDZ and their biosimilars.



Precision-guided dosing and individualized drug clearance to guide treatment decisions, increase the likelihood of achieving remission and of a durable, sustained response.

Visit the Prometheus booth
to learn how we can help you
advance precision-guided care.



Brandon Chatkin

Prometheus Senior Regional Technical Specialist
914-960-8455 | bchatkin@prometheuslabs.com

Prometheus tests are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. The tests may be covered by one or more US pending or issued patents - see prometheuslabs.com/patents. Prometheus, PredictrPK, Anser, Monitr and IBD sgi Diagnostic are registered trademarks of Prometheus Laboratories Inc., San Diego, California. All other trademarks or service marks are the property of their respective owners. ©2025 Prometheus Laboratories Inc. All rights reserved.

This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.